We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+3.98%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$77.4B
AUM Growth
-$741M
(-0.95%)
Cap. Flow
-$676M
Cap. Flow
% of AUM
-0.87%
Top 10 Holdings %
Top 10 Hldgs %
26.17%
Holding
1,421
New
35
Increased
882
Reduced
429
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$347M |
| 2 |
RTX Corp
RTX
|
+$322M |
| 3 |
Synopsys
SNPS
|
+$228M |
| 4 |
Cadence Design Systems
CDNS
|
+$227M |
| 5 |
Manhattan Associates
MANH
|
+$222M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$383M |
| 2 |
Broadcom
AVGO
|
+$320M |
| 3 |
Gilead Sciences
GILD
|
+$281M |
| 4 |
Newmont
NEM
|
+$261M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$238M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.99% |
| 2 | Materials | 26.22% |
| 3 | Healthcare | 8.42% |
| 4 | Industrials | 7.31% |
| 5 | Financials | 5.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
LeMaitre Vascular
LMAT
$1.8B
| $106K | ﹤0.01% |
1,266
+602
| +91% | +$56K |
|
1277
VTEX
VTEX
$747M
| $106K | ﹤0.01% |
20,857
-2,405
| -10% | -$13.7K |
|
1278
Guardant Health
GH
$21.9B
| $102K | ﹤0.01% |
2,384
-503
| -17% | -$21.7K |
|
1279
Vitamin Cottage Natural Grocers
NGVC
$736M
| $102K | ﹤0.01% |
2,530
+229
| +10% | +$9.58K |
|
|
OTLY
1280
Oatly Group
OTLY
$444M
| $100K | ﹤0.01% |
10,160
+7,326
| +259% | +$79.3K |
|
|
BPMC
1281
DELISTED
Blueprint Medicines
BPMC
| $99K | ﹤0.01% |
1,116
| – | – |
|
1282
ATS Corp
ATS
$2.72B
| $95K | ﹤0.01% |
3,815
+1,332
| +54% | +$37.2K |
|
|
STKL
1283
DELISTED
SunOpta
STKL
| $94K | ﹤0.01% |
19,290
+1,220
| +7% | +$8.12K |
|
1284
Ally Financial
ALLY
$13.6B
| $93K | ﹤0.01% |
2,553
+181
| +8% | +$6.67K |
|
|
AZUL
1285
DELISTED
Azul
AZUL
| $93K | ﹤0.01% |
56,448
-6,890
| -11% | -$13.5K |
|
1286
Onto Innovation
ONTO
$13.7B
| $93K | ﹤0.01% |
769
+269
| +54% | +$45.3K |
|
|
SMC
1287
Summit Midstream
SMC
$417M
| $93K | ﹤0.01% |
+2,738
| New | +$110K |
|
1288
Fomento Económico Mexicano
FMX
$42.3B
| $82K | ﹤0.01% |
836
+35
| +4% | +$3.17K |
|
1289
Symbotic
SYM
$5.92B
| $81K | ﹤0.01% |
3,994
+1,393
| +54% | +$35.6K |
|
1290
Dr. Reddy's Laboratories
RDY
$10.1B
| $80K | ﹤0.01% |
6,086
+248
| +4% | +$3.42K |
|
1291
Ouster
OUST
$3.03B
| $77K | ﹤0.01% |
8,519
+2,973
| +54% | +$29.3K |
|
1292
New Jersey Resources
NJR
$5.59B
| $76K | ﹤0.01% |
1,555
+523
| +51% | +$24.8K |
|
1293
Quanta Services
PWR
$103B
| $74K | ﹤0.01% |
293
-27,700
| -99% | -$8M |
|
|
CVGW
1294
DELISTED
Calavo Growers
CVGW
| $72K | ﹤0.01% |
2,986
+444
| +17% | +$10.4K |
|
1295
iShares 7-10 Year Treasury Bond ETF
IEF
$47.3B
| $68K | ﹤0.01% |
708
+2
| +0.3% | +$187 |
|
1296
Ionis Pharmaceuticals
IONS
$9.01B
| $65K | ﹤0.01% |
2,157
-59,462
| -96% | -$1.95M |
|
1297
Ultragenyx Pharmaceutical
RARE
$2.45B
| $65K | ﹤0.01% |
1,793
+33
| +2% | +$1.37K |
|
1298
iRhythm Holdings
IRTC
$4.09B
| $58K | ﹤0.01% |
554
| – | – |
|
1299
Seneca Foods Class A
SENEA
$1.16B
| $53K | ﹤0.01% |
598
-131
| -18% | -$10.5K |
|
1300
Southwest Gas
SWX
$6.56B
| $52K | ﹤0.01% |
727
+1
| +0.1% | +$74 |
|
Similar funds
VanEck Associates's Q1 2025 Portfolio in Review
As of Q1 2025, VanEck Associates held 1,421 positions worth $77.4B, down 0.95% from $78.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 4.5%. VanEck Associates opened 35 new positions and exited 29, leaving the 1,421-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 41% a quarter earlier, followed by Materials and Healthcare.
- VanEck Associates's largest Q1 2025 buy was Philip Morris: 2,449,251 shares worth $389M.
- VanEck Associates added most to RTX Corp in Q1 2025, an estimated $322M increase.
- VanEck Associates's biggest Q1 2025 reduction was TSMC, cutting an estimated $383M.
- VanEck Associates fully exited Celestica in Q1 2025, selling an estimated $9.19M.
- VanEck Associates's ten largest holdings make up 26% of its $77.4B portfolio in Q1 2025.
- VanEck Associates opened 35 new positions and closed 29 in Q1 2025.
- VanEck Associates's portfolio value fell 0.95% quarter-over-quarter to $77.4B.
Based on VanEck Associates's 13F filing for Q1 2025, filed 15 May 2025.